❤️‍🩹 Case Study on Myocardial Infarction (STEMI)

Medical-Surgical Nursing | NANDA Nursing Care Plan Format

Cardiology Nursing | Practical File Ready

📋 Student Information

📄 Page 1 — Patient Identification Data

📄 Page 2 — Chief Complaints & Clinical History

CHIEF COMPLAINT

The patient was brought to the emergency department at 7:30 AM with the complaints of:

• Severe crushing retrosternal chest pain — sudden onset 2 hours ago
• Pain radiating to left arm, left shoulder, and jaw
• Profuse sweating (diaphoresis) — drenching clothes
• Shortness of breath at rest — unable to lie flat
• Nausea with 2 episodes of vomiting
• Feeling of impending doom (angor animi) — "I feel like I am going to die"
• Palpitations and dizziness

HISTORY OF PRESENT ILLNESS

The patient, Mr. Ramesh Chandra Gupta, a 62-year-old retired government officer, was apparently in his usual state of health until approximately 5:30 AM on 05/02/2026, when he experienced sudden onset of severe crushing retrosternal chest pain while at rest. The pain was described as "someone sitting on my chest" — heaviness and pressure type, 10/10 in severity, radiating to the left arm, left shoulder, and jaw. It was associated with profuse diaphoresis, shortness of breath, nausea with 2 episodes of vomiting, palpitations, and a sense of impending doom (angor animi).

The patient attempted self-medication at home — Sorbitrate 5mg sublingual × 2 doses at 15-minute intervals — but the pain was NOT relieved. His son then called emergency services (108 ambulance) and he was brought to the SMS Hospital Emergency Department at 7:30 AM.

On arrival to the Emergency Department, an immediate 12-lead ECG was performed, which revealed ST-segment elevation of 4mm in leads V1 through V4, consistent with acute anteroseptal wall myocardial infarction (STEMI). Blood was drawn for cardiac biomarkers. The patient was immediately started on the MONA protocol (Morphine, Oxygen, Nitrates, Aspirin) and shifted to the ICCU for initiation of thrombolytic therapy. Streptokinase 1.5 million units IV infusion was administered over 1 hour. Pain gradually reduced from 10/10 to 4/10 post-thrombolysis. ECG at 90 minutes post-thrombolysis showed >50% ST resolution, indicating successful reperfusion.

PAST MEDICAL HISTORY

• Hypertension — Diagnosed 15 years ago; on Tablet Amlodipine 5mg OD; average home BP 140/90 mmHg
• Type 2 Diabetes Mellitus — Diagnosed 8 years ago; on Tablet Metformin 500mg BD + Tablet Glimepiride 2mg OD before meals; recent HbA1c 8.2% (uncontrolled)
• Dyslipidemia — Diagnosed 5 years ago; on Tablet Rosuvastatin 10mg OD at bedtime
• No history of thyroid disorder, tuberculosis, asthma, or epilepsy
• No known drug or food allergies

PAST SURGICAL HISTORY

• No history of any major surgical intervention.
• No history of previous hospitalization for surgery or cardiac procedures.
• No history of blood transfusion.

📄 Page 3 — Family History & Composition

FAMILY HISTORY

• The patient belongs to a joint family.
• There are 7 members in the family — patient, wife, son, daughter-in-law, and 3 grandchildren.
• Father — suffered acute myocardial infarction at age 58; expired at age 68 due to recurrent MI.
• Mother — diagnosed with hypertension and type 2 diabetes mellitus; alive at age 82.
• Younger brother — diagnosed with coronary artery disease at age 55; underwent PTCA with stenting at age 56.
• Older sister — hypertensive; alive at age 66.
• Strong family history of premature coronary artery disease.

FAMILY COMPOSITION

FAMILY TREE

📄 Page 4 — Dietary, Personal, Socio-Economic & Environmental History

DIETARY HISTORY

• The patient takes a mixed diet — predominantly vegetarian with occasional non-vegetarian (1-2 times/week).
• Diet is characteristically high in saturated fats — regular consumption of full-cream milk, ghee, butter, fried foods (pakoras, samosas, puri).
• High salt intake — pickles, papad, namkeen consumed daily.
• High sugar intake — sweets (rasgulla, gulab jamun) 2-3 times per week; 3-4 teaspoons sugar in each cup of tea.
• Low intake of fresh fruits, vegetables, and dietary fiber.
• High caffeine intake — 5-6 cups of full-cream milk tea daily.
• Adequate fluid intake — approximately 2-2.5 liters/day including water and tea.
• No history of food allergy reported.

PERSONAL HISTORY

• Sleep: 5-6 hours per night; often disturbed sleep; wakes up 2-3 times to urinate (nocturia — possible early diabetic nephropathy).
• Appetite: Normal; prefers heavy meals
• Bowel: Once daily, regular; however tends to constipation due to low fiber intake
• Bladder: 6-7 times/day including 2-3 times at night (nocturia)
• Habits: Active smoker — 30 pack-years (10 cigarettes/day × 30 years); continued despite HTN and DM diagnosis. Alcohol — occasional whiskey (2-3 pegs/week, mostly on weekends).
• Activity level: Sedentary lifestyle; post-retirement spends most time at home watching TV, reading newspaper; no regular exercise or walking routine. Occasionally goes for morning walk but not consistent.
• Allergy: No known drug or food allergy.
• BMI: 30.5 kg/m² (Obese Class I)
• Waist Circumference: 108 cm (Abdominal obesity — central adiposity)

SOCIO-ECONOMIC HISTORY

• The patient belongs to a middle-class family.
• Total annual family income is approximately ₹5,00,000 per year (pension + son's income).
• The family lives in a joint family setup in their own house.
• Patient has access to medical facilities and health insurance (CGHS — Central Government Health Scheme).
• Son is the primary earning member; patient's pension supplements the household.

ENVIRONMENTAL HISTORY

• The family lives in their own pucca house with adequate ventilation and natural lighting.
• No exposure to industrial pollutants, chemicals, or radiation.
• Uses LPG (liquefied petroleum gas) for cooking — no biomass fuel exposure.
• Safe drinking water supply — RO (reverse osmosis) filtered water available.
• Living environment is clean and hygienic with proper sanitation facilities.

📄 Page 5 & 6 — Physical Examination

GENERAL CONDITION

Patient is conscious, oriented to time, place, and person. However, appears anxious, restless, and in acute distress due to chest pain on admission. Post-thrombolysis: Patient is comfortable, resting in semi-Fowler's position. Appears relieved but still anxious about prognosis.

VITAL SIGNS

• Temperature: 98.2°F (Afebrile)
• Pulse: 112 beats/min (Tachycardia — regular but rapid)
• Respiration: 28 breaths/min (Tachypnea — shallow)
• Blood Pressure: 160/100 mmHg (Hypertensive — Grade 2)
• SpO₂: 91% on room air (Hypoxia — requiring O₂ supplementation)
• Pain Score: 10/10 on Numeric Pain Rating Scale (Worst possible pain)

GENERAL APPEARANCE

• Built: Endomorphic; obese with central adiposity
• Posture: Prefers sitting up (orthopnea); unable to lie flat
• Activity: Restless; keeps touching chest; facial grimacing
• Speech: Short sentences due to dyspnea; voice anxious
• Signs of distress: Profuse diaphoresis; skin pale, cool, and clammy; tachypnea; nasal flaring

SYSTEMIC EXAMINATION

📄 Page 7 — Vital Signs Monitoring Record

📄 Page 8 — Diagnostic Investigations

📄 Page 9 — Medical Management (Drug Chart)

📄 Page 10 — Disease Introduction, Etiology & Pathophysiology

INTRODUCTION

Myocardial Infarction (MI), commonly known as a "heart attack," is a life-threatening medical emergency characterized by irreversible necrosis (death) of cardiac muscle cells (cardiomyocytes) due to prolonged and severe myocardial ischemia. It occurs when blood flow through one or more coronary arteries is abruptly reduced or completely blocked, depriving the myocardium of oxygen and nutrients.

MI is classified based on ECG findings into ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). STEMI, as seen in this patient, indicates complete transmural occlusion of a major epicardial coronary artery, typically caused by an occlusive thrombus superimposed on a ruptured or eroded atherosclerotic plaque. STEMI is the most severe form of acute coronary syndrome (ACS) and requires immediate, time-sensitive reperfusion therapy — either pharmacological (thrombolysis) or mechanical (primary percutaneous coronary intervention — PCI).

The phrase "Time is Muscle" reflects the critical importance of rapid treatment — myocardial necrosis begins within 20-40 minutes of complete occlusion and progresses from endocardium to epicardium as a "wavefront phenomenon." The extent of myocardial damage directly correlates with total ischemic time. Without timely reperfusion, complications including cardiogenic shock, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia), acute heart failure, myocardial rupture, and sudden cardiac death can occur.

ETIOLOGY

The primary pathological process underlying STEMI is coronary atherosclerosis — the buildup of cholesterol-rich plaque within the walls of coronary arteries over decades. The acute event (plaque rupture or erosion) triggers a cascade of platelet adhesion, activation, and aggregation, culminating in occlusive thrombus formation.

Common causes:

• Atherosclerotic plaque rupture with superimposed thrombus (most common — 90% of cases)
• Coronary artery spasm (Prinzmetal angina) — can occur with or without atherosclerosis
• Coronary artery dissection (spontaneous or iatrogenic)
• Coronary embolism (from atrial fibrillation, valvular disease, or infective endocarditis)
• Severe prolonged hypotension causing reduced coronary perfusion pressure

Major modifiable risk factors:

• Smoking: Single most important preventable risk factor; accelerates atherosclerosis; causes endothelial dysfunction; increases platelet aggregability; reduces HDL cholesterol. Risk decreases by 50% within 1 year of cessation.
• Hypertension: Causes endothelial injury through increased shear stress; accelerates atherogenesis; target BP <130/80 mmHg.
• Diabetes Mellitus: Considered a "coronary artery disease equivalent" — confers same risk as prior MI; causes diffuse, multi-vessel disease; accelerates atherosclerosis through advanced glycation end-products (AGEs).
• Dyslipidemia: Elevated LDL cholesterol (>100 mg/dL, optimally <70 for CAD patients) is the primary atherogenic lipoprotein; low HDL (<40 mg/dL) removes cardioprotection; elevated triglycerides contribute.
• Obesity: BMI >30 kg/m²; associated with insulin resistance, hypertension, dyslipidemia, and systemic inflammation.
• Physical inactivity: Sedentary lifestyle doubles CAD risk; regular exercise improves all modifiable risk factors.
• Psychosocial stress: Chronic stress, depression, and social isolation increase sympathetic activation, cortisol levels, and platelet reactivity.

Non-modifiable risk factors:

• Age (>45 years for men, >55 for women)
• Male gender
• Family history of premature CAD (first-degree male relative <55 years, female <65 years)
• Ethnicity (South Asians have 3-4× higher risk)

PATHOPHYSIOLOGY

The pathophysiology of STEMI can be understood as a sequential cascade:

1. Endothelial Injury and Plaque Formation: Risk factors (hypertension, smoking, hyperlipidemia, diabetes) cause endothelial dysfunction and injury to the coronary artery intima. This allows LDL cholesterol particles to infiltrate the subendothelial space, where they become oxidized (oxLDL). OxLDL is highly immunogenic and triggers an inflammatory response.

2. Inflammatory Response and Foam Cell Formation: Circulating monocytes adhere to the damaged endothelium via adhesion molecules (VCAM-1, ICAM-1) and migrate into the intima, transforming into macrophages. Macrophages express scavenger receptors that engulf oxidized LDL, becoming lipid-laden foam cells — the hallmark of early atherosclerotic lesions (fatty streaks).

3. Plaque Progression: Foam cells release pro-inflammatory cytokines (TNF-α, IL-1, IL-6), growth factors, and matrix metalloproteinases (MMPs). Smooth muscle cells migrate from the media to the intima, proliferate, and produce extracellular matrix (collagen, elastin). This forms a fibrous cap over the lipid-rich necrotic core — creating a mature fibroatheromatous plaque.

4. Plaque Instability and Rupture: Thin-cap fibroatheroma (TCFA) with a large lipid core (>40% of plaque volume), intense inflammatory cell infiltrate (macrophages, T-lymphocytes) at the shoulder regions, and reduced smooth muscle cell content are vulnerable to rupture. MMPs secreted by macrophages degrade the fibrous cap collagen. Sudden hemodynamic stress (e.g., surge in sympathetic activity in early morning, physical exertion, emotional stress) can trigger rupture of the weakened cap.

5. Thrombus Formation: Plaque rupture exposes highly thrombogenic subendothelial matrix (collagen, tissue factor, von Willebrand factor) to circulating blood. Platelets adhere to exposed collagen via glycoprotein Ib-IX-V receptors and von Willebrand factor. Adherent platelets become activated, change shape, degranulate, releasing ADP, thromboxane A₂, and serotonin. These mediators recruit and activate additional platelets. The coagulation cascade is simultaneously activated — tissue factor binds Factor VIIa, initiating the extrinsic pathway, culminating in thrombin generation. Thrombin converts fibrinogen to fibrin, which cross-links platelets, forming a stable, occlusive "white-red" thrombus.

6. Coronary Occlusion and Myocardial Ischemia: The occlusive thrombus completely blocks the coronary artery lumen (typically the left anterior descending artery for anteroseptal MI), abruptly stopping antegrade blood flow. Within seconds, the affected myocardium switches from aerobic to anaerobic metabolism. ATP depletion occurs within minutes. Ineffective anaerobic glycolysis produces only 2 ATP per glucose molecule (vs. 36 ATP aerobically), causing rapid energy failure.

7. Cellular Injury and Necrosis: ATP depletion causes failure of the Na⁺/K⁺-ATPase pump → intracellular Na⁺ accumulation → cellular edema. Failure of the Ca²⁺-ATPase pump → intracellular Ca²⁺ overload → activation of proteases, lipases, and endonucleases → structural protein degradation. The sarcolemmal membrane loses integrity → intracellular contents (troponin, CK-MB, myoglobin) leak into the bloodstream (cardiac biomarkers). Irreversible injury begins after 20-40 minutes of complete occlusion. Necrosis spreads as a "wavefront" from the subendocardium (most vulnerable to ischemia) toward the epicardium. The extent of necrosis depends on: (a) duration of occlusion, (b) presence of collateral circulation, (c) myocardial oxygen demand at the time of occlusion, and (d) ischemic preconditioning.

8. Myocardial Stunning and Remodeling: Even after successful reperfusion, the salvaged myocardium may remain temporarily dysfunctional ("stunned myocardium") due to reperfusion injury (oxidative stress, calcium overload, inflammation). Over weeks to months, the infarct zone thins and expands (infarct expansion), while the non-infarcted myocardium undergoes compensatory hypertrophy and dilation — collectively termed "ventricular remodeling." This process, if unchecked by ACE inhibitors and beta-blockers, leads to progressive left ventricular dilation, systolic dysfunction, and clinical heart failure.

📄 Page 11 — Clinical Manifestations, Diagnostic & Medical Management

CLINICAL MANIFESTATIONS

The patient presented with classic features of acute STEMI:

• Chest Pain: Sudden onset, severe crushing retrosternal chest pain ("heaviness," "pressure," "someone sitting on my chest"), 10/10 intensity, radiating to left arm (medial aspect), left shoulder, and jaw. Not relieved by rest or sublingual nitrates (×2 doses). Lasting >30 minutes (2+ hours at presentation).
• Diaphoresis: Profuse, cold, clammy sweating — drenching clothes. Result of sympathetic nervous system activation and cardiogenic reflex.
• Dyspnea: Shortness of breath at rest; unable to lie flat (orthopnea). Result of acute pulmonary congestion due to transient LV dysfunction — elevated left ventricular end-diastolic pressure (LVEDP) → increased pulmonary capillary wedge pressure → fluid transudation into pulmonary interstitium and alveoli.
• Nausea and Vomiting: 2 episodes. Result of vagal stimulation (Bezold-Jarisch reflex) and/or inferior wall involvement stimulating the diaphragm.
• Angor Animi: "Feeling of impending doom" — patient explicitly stated "I feel like I am going to die." A characteristic and highly specific symptom of acute MI.
• Palpitations and Dizziness: Sensation of rapid, irregular heartbeat; lightheadedness. May indicate sinus tachycardia, atrial fibrillation, or ventricular ectopy.
• Pallor and Cool Extremities: Peripheral vasoconstriction due to sympathetic activation and reduced cardiac output.

DIAGNOSTIC EVALUATION

Diagnosis of STEMI is based on the triad of: (1) Clinical presentation (chest pain), (2) ECG changes (ST elevation), (3) Cardiac biomarkers (elevated Troponin).

• 12-Lead ECG (Admission): ST-segment elevation of 4mm in leads V1-V4 (anteroseptal leads). Reciprocal ST depression in inferior leads (II, III, aVF). Developing Q waves in V1-V3. This pattern is diagnostic of acute anteroseptal STEMI, indicating occlusion of the left anterior descending (LAD) coronary artery, most likely proximal to the first septal perforator.
• ECG (90 minutes Post-Thrombolysis): >50% ST-segment resolution in anterior leads — a marker of successful pharmacological reperfusion. Evolving T-wave inversion (reperfusion T-waves).
• Cardiac Troponin I (High-Sensitivity): 12,400 ng/L (normal <34 ng/L) — markedly elevated, >365× upper reference limit. Troponin is the gold-standard cardiac biomarker — highly specific for myocardial necrosis. Levels rise within 3-6 hours, peak at 12-24 hours, and remain elevated for 7-14 days.
• CK-MB: 186 U/L (normal <25 U/L) — elevated, >7× normal. Rises within 4-6 hours, peaks at 18-24 hours, returns to normal in 48-72 hours. Useful for detecting reinfarction due to shorter half-life.
• 2D Echocardiography: LVEF 40% (moderately reduced; normal ≥55%). Regional wall motion abnormality — anteroseptal and apical akinesia (no thickening during systole). Mild mitral regurgitation (functional — due to papillary muscle dysfunction). No intracardiac thrombus, ventricular septal rupture, or pericardial effusion.
• Lipid Profile: LDL 156 mg/dL (critically elevated for CAD patient — target <70), HDL 31 mg/dL (low), Triglycerides 228 mg/dL (elevated), Total Cholesterol 246 mg/dL.
• Glycemic Assessment: FBS 168 mg/dL, HbA1c 8.2% — indicates chronic uncontrolled diabetes.
• Chest X-Ray: Mild pulmonary venous congestion; no frank pulmonary edema; normal cardiac silhouette size; no pleural effusion.

MEDICAL MANAGEMENT

The patient received standard evidence-based STEMI management according to ACC/AHA and ESC guidelines:

• Immediate MONA Protocol in Emergency Department: Morphine 4mg IV (pain relief + anxiolysis + venodilation reducing preload), Oxygen 4L/min via nasal cannula (SpO₂ <94% — hypoxia correction), Sublingual Nitrates (Sorbitrate 5mg ×2 — coronary vasodilation; pain not relieved indicating severe occlusion), Aspirin 325mg chewed (rapid COX-1 inhibition — antiplatelet).
• Reperfusion Therapy — Pharmacological Thrombolysis: Streptokinase 1.5 million IU IV infusion over 60 minutes. Streptokinase is a non-fibrin-specific thrombolytic agent that forms a complex with plasminogen, converting it to plasmin, which degrades fibrin clot. Indicated in STEMI within 12 hours of symptom onset when primary PCI is not immediately available. Successful reperfusion confirmed by >50% ST resolution at 90 minutes, reduction in chest pain (10/10→4/10), and absence of reperfusion arrhythmias.
• Dual Antiplatelet Therapy (DAPT): Aspirin 150mg OD (lifelong) + Clopidogrel 75mg OD (minimum 12 months). DAPT is the cornerstone of secondary prevention — prevents stent thrombosis (if PCI performed) and recurrent atherothrombotic events.
• High-Intensity Statin: Atorvastatin 80mg OD at bedtime — aggressive LDL lowering (target <70 mg/dL for very high-risk CAD patients), plaque stabilization, anti-inflammatory pleiotropic effects.
• Beta-Blocker: Metoprolol Succinate 50mg BD — reduces myocardial O₂ demand by lowering heart rate, contractility, and blood pressure. Reduces mortality post-MI by 25-30% by preventing ventricular arrhythmias and reducing infarct size.
• ACE Inhibitor: Ramipril 5mg OD — prevents adverse ventricular remodeling by blocking angiotensin II-mediated cardiac fibrosis and hypertrophy. Reduces mortality and heart failure post-MI. Especially indicated in anterior MI with LV dysfunction (LVEF 40% in this patient).
• Cardiac Rehabilitation: Phase I (inpatient) initiated — gradual mobilization, risk factor education, psychosocial counseling. Phase II (outpatient) planned post-discharge — structured exercise program, dietary counseling, smoking cessation, stress management.

📄 Page 12 — Nursing Management, Health Education, Prognosis & Conclusion

NURSING MANAGEMENT

Nursing care of the acute MI patient is comprehensive, encompassing vigilant physiological monitoring, meticulous medication administration, early recognition and management of life-threatening complications, and holistic psychosocial support:

• Immediate Triage and Rapid Assessment: Triage within 10 minutes of arrival to Emergency Department. Rapid focused history — PQRST pain assessment (Provocation, Quality, Radiation, Severity, Timing). Obtain 12-lead ECG within 10 minutes of arrival. Establish IV access (2 large-bore IV cannulae). Draw blood for cardiac biomarkers (Troponin I, CK-MB), coagulation profile, complete blood count, renal function, electrolytes.
• Continuous Cardiac Monitoring: Continuous ECG monitoring in ICCU — lead II and V1 for optimal rhythm and ST-segment monitoring. Observe for ventricular arrhythmias — premature ventricular contractions (PVCs), ventricular tachycardia (VT), ventricular fibrillation (VFib) — which are the most common cause of death in first 24 hours post-MI. Immediately report and treat sustained VT/VFib with defibrillation/cardioversion per ACLS protocol. Monitor for atrial arrhythmias — atrial fibrillation (occurs in 10-20% of MI patients). Monitor for bradyarrhythmias — sinus bradycardia, AV blocks (especially with inferior MI).
• Vital Signs Monitoring: Every 15 minutes during acute phase (first 2 hours post-thrombolysis), every 30 minutes for next 2 hours, every 1 hour for next 4 hours, then every 4 hours once stable. Monitor for hypotension (SBP <90 mmHg — may indicate cardiogenic shock, right ventricular infarction, or bleeding). Monitor for hypertension (may increase myocardial O₂ demand and cause cardiac rupture). Monitor respiratory rate and SpO₂ continuously — titrate O₂ to maintain SpO₂ >94%.
• Pain Assessment and Management: Assess chest pain every 15-30 minutes using standardized pain scale (0-10). Document location, quality, radiation, associated symptoms. Administer Morphine 2-4mg IV every 5-15 minutes as prescribed until pain relief achieved. Monitor for Morphine side effects — respiratory depression (RR <12/min), hypotension, excessive sedation, nausea/vomiting. Keep Naloxone ready as antidote. Reassure patient that pain relief is a priority and report inadequate pain control to physician immediately.
• Thrombolytic Therapy Administration and Monitoring: Verify inclusion criteria (STEMI within 12 hours, ECG criteria met, no contraindications) and exclusion criteria (active bleeding, recent surgery/trauma, stroke within 3 months, severe uncontrolled hypertension >180/110, bleeding diathesis). Administer Streptokinase 1.5 million IU IV over 60 minutes. Monitor for reperfusion arrhythmias (common and usually self-limiting — accelerated idioventricular rhythm is a sign of successful reperfusion). Monitor for allergic reactions (Streptokinase is a foreign protein — risk of anaphylaxis; keep Hydrocortisone and Adrenaline ready). Monitor for bleeding complications — access sites, IV sites, gingival, gastrointestinal, intracranial. Avoid unnecessary venipunctures, IM injections, and arterial punctures during and for 24 hours post-thrombolysis.
• Strict Bed Rest with Gradual Mobilization: Complete bed rest for first 24 hours with bedside commode privileges. Semi-Fowler's position (head elevated 30-45°) to reduce venous return (preload), decrease myocardial workload, and improve ventilation. Passive range-of-motion exercises to prevent DVT. Gradual progressive mobilization starting Day 2 — sitting in chair for 15-30 minutes, progressing to short walks (5-10 minutes, 2-3 times daily). Avoid isometric exercises (increase afterload), Valsalva maneuver (causes bradycardia and hypotension), and straining during defecation (administer stool softeners — Lactulose or Docusate).
• Fluid and Hemodynamic Monitoring: Maintain strict intake-output chart. Monitor for signs of heart failure — worsening dyspnea, crackles extending upward, S3 gallop, decreased urine output, cold extremities. Monitor for signs of cardiogenic shock — hypotension, oliguria (<30 mL/hr), altered mental status, cool clammy skin, metabolic acidosis. Monitor for signs of right ventricular infarction (especially if inferior MI) — elevated JVP, clear lung fields, hypotension. Weigh patient daily — sudden weight gain may indicate fluid retention.
• Psychosocial Support and Anxiety Reduction: Acknowledge patient's fear and anxiety — "angor animi" is a real and terrifying symptom. Provide calm, reassuring environment. Explain all procedures, monitors, alarms before performing. Encourage verbalization of fears and concerns. Involve family members in care and education. Teach simple relaxation techniques — slow deep breathing, guided imagery. Consider spiritual support if patient desires (chaplain services). Monitor for signs of depression — common post-MI; screen using PHQ-2/PHQ-9.

HEALTH EDUCATION

• Medication Compliance (MOST CRITICAL): Patient was emphatically educated to NEVER STOP Aspirin or Clopidogrel without explicit cardiologist instruction. Premature DAPT discontinuation is the #1 cause of stent thrombosis (20-40% mortality) and recurrent MI. Use a weekly pill box organizer. Set mobile phone alarms for medication timings. Keep an updated medication card in wallet listing all drugs, doses, and timings. Inform any doctor, dentist, or surgeon about antiplatelet therapy before any procedure — NEVER stop on their advice alone without consulting cardiologist.
• Dietary Advice: Mediterranean diet — rich in fruits, vegetables, whole grains, legumes, nuts, and olive oil. Fish (especially fatty fish — salmon, mackerel) 2-3 times per week for omega-3 fatty acids. Strict salt restriction — <2 grams sodium per day (approximately 1 teaspoon). Remove salt shaker from dining table. Avoid processed foods (chips, namkeen, biscuits), pickles, papad, canned foods — hidden sources of sodium. Limit saturated fats — avoid ghee, butter, full-cream milk, red meat, organ meats. Use mustard oil or olive oil for cooking. Complete avoidance of trans fats — vanaspati, bakery products (cakes, pastries, biscuits), deep-fried fast foods. Limit sugar and refined carbohydrates. Use jaggery or honey in moderation if needed.
• Lifestyle Modification: Complete and permanent smoking cessation — ZERO tobacco in any form. Nicotine replacement therapy (NRT), bupropion, or varenicline available if needed. Referral to smoking cessation clinic. Avoid passive smoking (secondhand smoke). Limit alcohol — ideally complete cessation; if unavoidable, maximum 1 standard drink per occasion, not more than 2-3 times per week. Ensure adequate sleep — 7-8 hours per night. Establish regular sleep-wake schedule. Practice sleep hygiene — avoid caffeine after 4 PM, avoid screen time before bed.
• Exercise and Activity: Phase I cardiac rehabilitation (inpatient) — gradual mobilization and self-care activities. Phase II (outpatient supervised program) — starting 1-2 weeks post-discharge. Structured aerobic exercise — walking, stationary cycling — 30-45 minutes, 3-5 times per week. Progressive resistance training — light weights after 4-6 weeks. Avoid heavy weightlifting, competitive sports, and isometric exercises initially. Monitor heart rate during exercise — target HR = resting HR + 20-30 bpm initially. STOP if chest pain, dyspnea, dizziness, or palpitations occur.
• Disease Awareness: Explained in simple Hindi/English that MI occurred due to blockage in the heart's blood vessel (LAD artery). The thrombolytic injection dissolved the clot and restored blood flow. However, the underlying cholesterol plaque remains — medications (Aspirin, Clopidogrel, Atorvastatin) and lifestyle changes prevent future blockage. Stressed that MI is a "wake-up call" — lifelong commitment to heart-healthy living required.
• Follow-up Care: First cardiologist follow-up: 2 weeks after discharge — medication review, BP check, wound check. Lipid profile and HbA1c: 4-6 weeks — to assess statin efficacy and glycemic control. 2D Echocardiogram: 3 months — reassess LVEF and regional wall motion. Stress test (Treadmill Test): 6 months — assess functional capacity and residual ischemia. Annual comprehensive cardiac evaluation — ECG, Echo, TMT, lipid profile, HbA1c, renal function. Dental check-up — important for preventing infective endocarditis (though not routinely indicated for post-MI alone). Advised to immediately report to ER (call 108) if: Chest pain at rest lasting >5 minutes, sudden shortness of breath, palpitations with dizziness, black/tarry stools (GI bleeding from antiplatelets), sudden severe headache (possible intracranial hemorrhage), or rapidly progressive leg swelling/pain (possible DVT).

PROGNOSIS

With successful pharmacological reperfusion and guideline-directed medical therapy, the prognosis of anterior STEMI has improved significantly in the modern era. In-hospital mortality for STEMI treated with thrombolysis is approximately 5-7%. However, this patient has several high-risk features that warrant careful monitoring and aggressive secondary prevention: moderate LV dysfunction (LVEF 40%), anterior wall MI (worse prognosis than inferior MI), multiple uncontrolled risk factors (HbA1c 8.2%, LDL 156, ongoing smoking, obesity), and strong family history of premature CAD. LVEF is the single most important predictor of long-term survival post-MI — patients with LVEF <40% have significantly higher 5-year mortality. With optimal medical therapy, cardiac rehabilitation, and lifestyle modification, significant LVEF recovery is possible (stunned myocardium recovery). The patient and family were counseled regarding the serious nature of the condition balanced with realistic optimism — with adherence to treatment, a good quality of life is achievable.

CONCLUSION

This case study presents Mr. Ramesh Chandra Gupta, a 62-year-old male with multiple cardiovascular risk factors who suffered an acute anteroseptal STEMI due to complete LAD occlusion. Timely diagnosis with ECG and cardiac biomarkers, immediate initiation of MONA protocol, and prompt thrombolytic therapy with Streptokinase achieved successful reperfusion (>50% ST resolution, complete pain relief, no complications).

This case underscores that STEMI management is a race against time — "Time is Muscle" — where every minute of delay results in irreversible cardiomyocyte loss. The critical role of the emergency nurse and ICCU nurse spans the entire care continuum: rapid triage and ECG acquisition, vigilant monitoring for life-threatening arrhythmias and mechanical complications, meticulous administration and monitoring of thrombolytic and antithrombotic therapy, comprehensive pain management, early mobilization and cardiac rehabilitation, thorough patient and family education, and seamless discharge planning with follow-up coordination.

The most crucial nursing intervention for this patient's long-term survival is ensuring he understands the absolute necessity of lifelong medication adherence — especially DAPT — and empowers him with the knowledge and motivation to transform his lifestyle. A heart attack is not just a cardiac event; it is a life-changing experience that demands a compassionate, holistic nursing approach addressing physical, psychological, social, and spiritual dimensions of care.

📄 Page 13 — NANDA Nursing Diagnoses

📄 Page 14-16 — Nursing Care Plans (NANDA Format)

Nursing Care Plan — 1: Acute Pain

Nursing Care Plan — 2: Decreased Cardiac Output

Nursing Care Plan — 3: Anxiety

📄 Page 17 — Discharge Summary

Mr. Ramesh Chandra Gupta, 62-year-old male, was admitted to SMS Hospital, Jaipur on 05/02/2026 at 7:30 AM with acute onset crushing retrosternal chest pain (2 hours duration), diaphoresis, dyspnea, nausea, and angor animi. ECG revealed ST elevation 4mm in V1-V4 — diagnosed as Acute Anteroseptal Wall STEMI. He received immediate MONA protocol and successful pharmacological reperfusion with Streptokinase 1.5 MU IV (pain 10/10→4/10, >50% ST resolution at 90 minutes). Troponin I peaked at 12,400 ng/L; 2D Echo showed LVEF 40% with anteroseptal akinesia.

The patient had an uncomplicated hospital course — no arrhythmias, no heart failure, no bleeding complications, and no recurrent ischemia. Chest pain resolved completely by Day 2. Vital signs normalized (HR 78, BP 124/76, SpO₂ 98% on room air) by Day 4. He was gradually mobilized and participated actively in Phase I cardiac rehabilitation. He and his wife received comprehensive education regarding DAPT, cardiac diet, lifestyle modification, and follow-up care.

He is being discharged on Day 5 in stable condition on guideline-directed medical therapy including DAPT (Aspirin 150mg OD + Clopidogrel 75mg OD), high-intensity statin (Atorvastatin 80mg HS), beta-blocker (Metoprolol 50mg BD), ACE inhibitor (Ramipril 5mg OD), and antidiabetic medications. He has been enrolled in the Phase II outpatient cardiac rehabilitation program with first follow-up in 2 weeks.

At discharge, the patient is advised to:

• NEVER STOP Aspirin or Clopidogrel without explicit cardiologist approval — premature discontinuation can cause fatal stent thrombosis or reinfarction
• Take all medications exactly as prescribed at the same time daily — use pill box organizer and phone alarms
• Keep an updated medication card in wallet listing all drugs, doses, timings, and allergies
• Inform any doctor, dentist, or surgeon about antiplatelet therapy before any procedure
• Follow strict cardiac diet — low saturated fat, low salt (<2g sodium/day), Mediterranean diet principles
• Complete and permanent smoking cessation — ZERO tobacco; avoid passive smoking
• No alcohol
• Gradual progressive exercise — start with 10-15 minute walks, 2-3 times daily; increase by 5 minutes per week
• Enroll in and attend Phase II cardiac rehabilitation program (enrollment initiated)
• Avoid heavy weightlifting (>10 kg), competitive sports, and isometric exercises for 6 weeks
• No driving for 2 weeks post-discharge
• Sexual activity can be resumed after 2-4 weeks if asymptomatic (able to climb 2 flights of stairs without symptoms)
• Monitor BP at home 2-3 times weekly; maintain BP log
• Monitor blood sugar — fasting and post-prandial at least twice weekly
• Attend first cardiologist follow-up in 2 weeks; repeat lipid profile and HbA1c in 4-6 weeks
• Report IMMEDIATELY to Emergency (call 108) if: Chest pain at rest lasting >5 minutes; sudden shortness of breath; palpitations with dizziness or fainting; black/tarry stools or blood in vomit (signs of GI bleeding from antiplatelets); sudden severe headache with weakness/numbness (signs of intracranial hemorrhage); rapidly progressive leg swelling/pain (signs of DVT)

📄 Page 18 — Health Education

📄 Page 19 — Bibliography

1. Brunner, L.S. & Suddarth, D.S. (2022). Textbook of Medical-Surgical Nursing (15th ed.). Wolters Kluwer. Chapter 27: Management of Patients with Coronary Vascular Disorders, pp. 752-812.
2. NANDA International. (2024). Nursing Diagnoses: Definitions and Classification 2024-2026 (13th ed.). Thieme Medical Publishers.
3. Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. (2024). Fourth Universal Definition of Myocardial Infarction. Circulation, 138(20), e618-e651. American Heart Association.
4. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. (2023). 2023 ACC/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 82(4), e51-e200.
5. Ibanez, B., James, S., Agewall, S., et al. (2024). 2024 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation. European Heart Journal, 39(2), 119-177.
6. Kumar, V., Abbas, A.K., & Aster, J.C. (2024). Robbins and Cotran Pathologic Basis of Disease (11th ed.). Elsevier. Chapter 12: The Heart, pp. 521-580.
7. Doenges, M.E., Moorhouse, M.F., & Murr, A.C. (2024). Nursing Care Plans: Guidelines for Individualizing Client Care Across the Life Span (11th ed.). F.A. Davis Company.
8. World Health Organization. (2025). Cardiovascular Diseases (CVDs) — Fact Sheet. WHO, Geneva.

© Nursing Study Vault | NANDA Format Case Study | Myocardial Infarction (STEMI)